Cost‐effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen‐detected Type 2 diabetes: analysis of the ADDITION‐UK cluster‐randomized controlled trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 907-919

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of the psycho‐educational blended (group and online) intervention HypoAware compared with usual care for people with Type 1 and insulin‐treated Type 2 diabetes with problematic hypoglycaemia: analyses of a cluster‐randomized controlled trial

By  

DIABETIC MEDICINE, Vol. 35, Iss. 2, 2018-02 ,pp. : 214-222

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 18, Iss. 10, 2016-10 ,pp. : 1034-1040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of a risk‐based secondary screening programme of type 2 diabetes

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 32, Iss. 7, 2016-10 ,pp. : 710-729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 590-598

John Wiley & Sons Inc

Access to resources Recommend Favorite